Blogs
Dawn Dufield, PhD is the Scientific Officer for Mass Spectrometry and has been with KCAS Bio since 2018. Before joining KCAS Bio, she worked in the quantitative large and small molecule LC-MS/MS field for Pfizer for over 20 years. Dawn has been a pioneer in the Hybrid LCMS field and…
Videos
Dawn Dufield, Ph.D. and Dominic Warrino, Ph.D. discuss their approach to ligand binding assays (LBAs) and hybrid mass spectrometry (Hybrid LC-MS/MS) in this 11-part video series. What Makes a Good CRO for Bioanalysis? Are there any specific technologies that are more useful to have together? What is a Hybrid…
Blogs
In the scientific field, the often neglected fifth sense, the sense of smell, contributes to broadening our understanding of various phenomena, particularly in the field of biomarkers.Here, we will guide you along our lines of thought on the importance of our olfactory sense, and how it contributes to scientific exploration…
Webinars
For researchers and professionals working in the biopharmaceutical industry, an upcoming Bioanalysis Zone Panel Discussion will offer a unique opportunity to stay informed about the latest advancements in quantitative analysis techniques. Research projects can only succeed when selecting the appropriate biopharmaceutical quantification technique. Staying up-to-date on…
Blogs
In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront of these…
Webinars
Produced by AAPS Organized by Sciex Recorded on December 6, 2023 eChalkTalk available here. Webinar Description: In this webinar, scientists from KCAS Bio, along with specialists from SCIEX Biopharma & Pharma Solutions discuss • Developing robust assays for PD biomarkers and their challenges…
November 15
- November 17
Along with a series of studies we plan to present related to our experiences with hybrid LC-MS/MS technology, KCAS will also be presenting on a study where we analyzed a compound that involved looking at urea in plasma and lung fluid (urea, of course, being a biomarker). Urea is endogenous…
November 15
- November 17
For years, Dawn Dufield, PhD and I have been doing our best to get the word out (via as many venues as possible) about KCAS’s unique expertise with hybrid LC-MS/MS. This year’s upcoming EBF meeting in Barcelona is just such an opportunity, and one we are very much looking…
Blogs
The Pharm/Biotech industry’s main focus is on development of therapeutics to address unmet medical needs but sometimes, clinical trials lead to observations that lead to a change in research path for a drug. A good example is sildenafil that was originally studied for use in hypertension and angina pectoris. Observed…
Blogs
Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the development of New…
Blogs
With recent guidance released from the FDA, there are changes for PKs (Pharmacokinetics) and ADCs (Antibody Drug Conjugates) that must be clearly understood before making decisions for your drug product testing. ADCs combine the target specificity of monoclonal antibodies with the…
Blogs
In the world of scientific research and development, certain analytes pose unique challenges that require specialized expertise to overcome. Oligonucleotides, a class of analytes consisting of short DNA or RNA sequences, are notorious for their complexity and demanding nature. With their increasing importance in the…